Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis

NCT: NCT07122518 · RECRUITING

NCT IDNCT07122518
StatusRECRUITING
Start Date2026-06-23
Completion2028-06
SponsorCordis US Corp. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of the clinical investigation is to characterize clinical outcomes and to assess the real-world use of the commercial PALMAZ MULLINS XD™ Pulmonary Stent.

Frequently Asked Questions

What is Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis?

Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis is a clinical trial registered under NCT07122518. Current status: RECRUITING.

What is the status of NCT07122518?

The current status of NCT07122518 (Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis) is: RECRUITING.

When did Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis start?

Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis started on 2026-06-23.

Related Devices

PMA P220004Pulmonary stentCordis US Corp PMA P120002STENT, SUPERFICIAL FEMORAL ARTERYCordis US Corporation K221832SABER .014 PTA Dilatation Catheter; SABERX .014 PTA Dilatation CatheterCordis US Corp K230704RAIN Sheath™ Tibial Pedal IntroducerCordis US Corp K232573INFINITI™ Ambi Angiographic CatheterCordis US Corp

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑